FI~. 1. P1 and P2 are DMBA induced sarcomas in DA rats. PM represents a spontaneous sarcoma in L.BN rats. P1 tumor cells were cloned and recloned by limiting dilution. Tumor cells from P1 clone 9 are susceptible and tumor cells from P1 clone 10 are resistant to lysis by DA anti-Pl-specific killer T ceils (16) . Such cytolytic T cells clones are established as described under Material and Methods. Six different clones (1-6) were used for CML as described in Material and Methods using an effector/target cell ratio of 5:1.
syngeneic animals as described for P1 and P2. The characteristics of the tumor cell lines have been described elsewhere (15, 16) . The human cell line K562 and mouse lymphoma YAC-I were kept in vitro using Iscove's medium complemented with 10% FCS.
Preparation of Lymphoid Cell Suspensions and Rat T Lymphocytes.
Rats were killed over carbon dry ice. Spleen and lymph nodes were aseptically removed. Single-cell suspensions were prepared in phosphate-buffered saline (PBS) (Ca ++ and Mg +÷ free) using a stainless steel mesh. Erythrocytes were lysed by hypotonic shock using 0.9 ml of distilled water for 2 s followed by 0.1 ml of 10-times concentrated PBS. T lymphocytes were purified on 1.5 × 10 cm Ig anti-Ig columns (17) using sterile glass beads 80-120 mesh (Serva, Heidelberg, Federal Republic of Germany).
Preparation of T Cell Growth Factor (TCGF; Concanavalin A Supernatant).
Rat spleen cells were cultured in Eagles high amino acid (EHAA) medium (18) complemented with 0.5% fresh normal BN rat serum and 5 X 10 -~ M 2-mercaptoethanol (2-ME) and stimulated with 5/~g/ml of concanavalin A (Pharmacia Fine Chemicals, Uppsala, Sweden). 40 ml of a suspension containing 5 X l0 s cells per ml were cultured in a 3024 Falcon tissue tissue culture flask (Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, CA), and the supernatant was harvested 48 h later.
Restimulation of Primed DA T Lymphocytes with Antiidiotypic Antibodies. DA rats were immunized by six subcutaneous injections of 2 × 107 12,500-rad irradiated P1 sarcoma cells at 2-wk intervals. T lymphocytes from primed rats were stimulated with antiidiotypic antibodies in 3013 Falcon tissue culture flasks using EHAA medium complemented with 5 × 10 -s M 2-ME and 0.5% fresh normal BN rat serum as described (15) . Antiidiotypic antiserum was used at were collected on day 6 of culture and purified over Ficoll-Paque (19) . Cells were expanded on DA macrophages and TCGF in the following way: Macrophages were harvested from the peritoneal cavity of DA rats, washed once, and irradiated with 2,500 rad. Macrophages obtained from one rat were distributed over three 3013 tissue culture flasks and cultured in 5 ml EHAA-medium complemented with 10% FCS, 5 X 10 -5 M 2-ME, and 20% TCGF for 24 h. 10 ml of a suspension containing 1.25 × 106 purified restimulated T cells (see above) in EHAA medium complemented with 10% FCS, 20% TCGF, 5 X 10 -~ M 2-ME, and 0.05% antiidiotypic antiserum was added to each flask. Cells were harvested 1 wk later and cloned and recloned on syngeneic macrophages by limiting dilution (16) . Cytotoxic clones were selected and expanded as described above.
Cell-mediated Cytotoxicity Assay (CML). CML was performed in round-bottomed microtiter
plates (Cook M24 ART; Greiner, Nuertingen, Germany) in 200 /11 EHAA medium complemented with 5 × 10 -~ M 2-ME and 5% heat-inactivated FCS. Assays were performed in triplicates with effector/target cell ratios as indicated in Figures using 104 SICr-labeled target cells. The latter were prepared as described previously (16) . Plates were incubated for 6 h at 37°C in 5% CO2 in air. 100/tl of the supernatant was counted in the gamma counter. Percent cytotoxicity is expressed as 100 × [(experimental -spontaneous ~lCr release)/(maximalspontaneous 5iCr release)].
Preparation of Antiidiotypic Antisera in DA Rats. DA anti-Pl-specific antibodies were purified on paraformaldehyde-fixed P1 sarcoma cells as described previously (15) . 4 mg of purified anti-P 1 antibody was cross-linked with glutaraldehyde and injected together with complete Freund's adjuvant into 10 DA rats as described (20) . The antiidiotypic nature of the harvested sera was 
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Anti-P1 T Cell Clones No. Fro. 3. Same type of experiment as described in the legend to Fig. 2 , T cell clones 1-6 were tested against ~lCr-labeled tumor cells from P] clone 9 (A). Unlabeled K562 tumor cells were used for cold target inhibition at ratios of cold/hot target of 100:1 (B), 50:1 (C), 25:1 (D), and 1:1 (E). YAC-I cells were used for cold target inhibition at ratios of 100:1 (F), 50:1 (G), 25:1 (H), and 1:1 (I).
determined by a solid-phase radioimmunoassay or by the restimulation assay using Pl-primed DA T lymphocytes (15) .
Results and Discussion
Our system involves the use of DMBA-induced sarcomas in DA rats, which allows the induction of tumor-specific T cell clones as well as production of corresponding auto-antiidiotypic antibodies (15) . Such antibodies used at low concentration in the presence of TCGF can be used to selectively maintain specific T cell clones in vitro. In this system we have isolated six different T cell clones, all with idiotypic receptors and specific lytic ability for the relevant tumor (see Fig. 1 ). Two of these six clones, in addition, display a lytic profile identical to rat NK cells (see Fig. 1 ). This NK-like activity of clones 1 and 2 developed gradually during in vitro culture (16) and was discovered by specificity controls. Using cold target inhibition in a crisscross manner, we tested whether the very same cells in clones 1 and 2 display cytotoxic T lymphocyte (CTL) as well as NK specificity. Data shown in Figs. 2, 3 , and 4 demonstrate that this is true. Two NK targets, YAC-1 and K562, block clone 1 and 2 (but not clone 3-6) effector cells from lysing the T cell-sensitive DA tumor P 1-clone 9, It is of importance that Pl-clone 9 target cells are resistant to normal splenic NK cells (see Fig. 5 ). In complete correspondence, P 1-clone 9 targets could block the ability of T killer cell clones 1 and 2 to lyse either YAC-1 or K562 target cells (see Fig. 4 ).
It was crucial to establish whether clone 1 and 2 effector cells were using the same receptors to recognize the tumor-specific antigens on Pl-clone 9 targets as those used to bind to YAC-1 or K562 cells. To answer this question we used antiidiotypic antibodies in the presence or absence of complement (Fig. 6 ). Such antibodies in the presence of complement did wipe out all cytolytic activity in the clones regardless of the target type analyzed. However, at high concentration and in the absence of complement, a clear-cut selectivity of inhibition as to target type became apparent. Thus, clones 1 and 2 became inhibited in their reactions to P1 clone 9 targets (like the other clones), but were not suppressed at all in their reactivity towards the NK targets YAC-1 and K562. This strongly suggests the simultaneous presence of two distinct physically independent receptor types on clone 1 and 2 killer T cells: one that is idiotypic and antigen specific, and another displaying the binding profile of NK cells. Our results demonstrate the possibility of the simultaneous expression of two distinct lytic systems with different specificities in the same T cell. Such parallel display may of course yield combined specificity profiles endowing the individual cell with a selectivity distinct from most normal CTL or NK cells. This could thus well explain existing controversies as to the specificities encountered when using immuneactivated effector cells (21) .
A second note of interest is the ability of these "double-expressing" T cells to lyse target cells (K562) devoid of major histocompatibility complex (MHC) antigens. Conventional cytolytic T cells normally fail to kill MHC-lacking targets, e.g., teratocarcinoma cells (22) and an NK-like receptor may be necessary here to allow such . NK cells were also tested against the classical NK targets YAC-1 (A) and K562 (A) under the same conditions. Lyric capacity against YAC-I and K562 targets was also tested in the presence of 3% antiidiotypic antiserum of specificity DA anti-(DA anti@l) (15, 16) (B) or 3% DA normal serum (C).
lysis to occur. Whether such a receptor will indeed act as a triggering unit for the induction of a potential lytic machinery, like the IgG antibodies in antibody-dependent cellular cytotoxicity systems (23) , is an important issue. Recent studies (14) have indicated that the ability to express an NK-like binding specificity is a feature that can be found on several types of bone marrow-derived cells. Our findings should thus not be considered as evidence for the inclusion of the conventional NK cells within the T cell lineage. The combination of lytic ability and NK binding specificity may, therefore, in a normal situation, be something uniquely restricted to the distinct cell type classically defined as an NK cell. Situations leading to the induction of lytic capacities in normally nonlytic cells may thus create an NK-like activity in non-NK effector cell types. Depending on the frequency of cells expressing NK-binding activity in such populations, one should expect the appearance, upon activation, of cells with dual specificities in the manner reported in this study.
SuF[llTlary Dimethylbenzanthracene-induced P1 sarcoma cells induce Pl-specific antibodies in syngeneic DA rats. Antiidiotypic antibodies of specificity DA anti-(DA anti-P1) were induced against the tumor-specific antibodies and used to restimulate P l-primed DA T cells in vitro. Using antiidiotypic antibodies and T cell growth factor, P1-specific cytotoxic DA T cell clones were established by limiting dilution and kept in vitro. Two of these clones acquired during culture periods in addition to the P1 specificity lytic activity towards natural killer (NK) targets YAC-1 or K562. Cold target inhibition experiments showed that the very same cytotoxic T cells kill P1 and NK targets. Antiidiotypic antibodies of specificity DA anti-(DA anti-P1) inhibited cytotoxicity against P l but not against YAC-1 or K562. We conclude that two independent receptors are located on these double-reactive T cell clones, one that is idiotypic and antigen-specific, and another displaying the binding profile of NK cells.
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